1,289 results match your criteria Uveitis Intermediate


Indications and effects of biological agents in the treatment of noninfectious uveitis.

Immunotherapy 2022 Jun 13. Epub 2022 Jun 13.

Ophthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, P.R. China.

Noninfectious uveitis is a common blinding eye disease, and an autoimmune response is involved in its pathogenesis. Biological agents have gradually been introduced into the treatment of noninfectious uveitis. The authors reviewed the clinical application and side effects of different biological agents on noninfectious uveitis. Read More

View Article and Full-Text PDF

Letter to the Editor: Changes in Choroidal Vascularity Index in Intermediate Uveitis.

Transl Vis Sci Technol 2022 Jun;11(6)

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana," University of Salerno, via S. Allende 84081, Baronissi, Salerno, Italy. e-mail:

View Article and Full-Text PDF

Author Response: Changes in Choroidal Vascularity Index in Intermediate Uveitis.

Transl Vis Sci Technol 2022 Jun;11(6)

National Eye Institute, National Institutes of Health, Bethesda, MD, USA.

View Article and Full-Text PDF

Clinical course of HTLV-1 infection associated intermediate uveitis.

Arch Soc Esp Oftalmol (Engl Ed) 2022 May 24. Epub 2022 May 24.

Departamento de Retina, Oftálmica Clínica de la Visión, Lima, Peru.

Objective: To describe the clinical features at presentation, delivered treatment and follow-up of a case series of human T-cell lymphotropic virus type 1 (HTLV-1) associated intermediate uveitis.

Patients And Methods: Retrospective, descriptive and longitudinal study of patients with HTLV-1 associated intermediate uveitis treated at a reference ophthalmology facility in Lima, Peru, during the years 2012 to 2018.

Results: A total of 18 patients (28 eyes) were included, the average age at presentation was 57. Read More

View Article and Full-Text PDF

Predictors of glaucoma in patients with uveitis and scleritis.

Eye (Lond) 2022 May 24. Epub 2022 May 24.

Department of Ophthalmology, Auckland District Health Board, Auckland, New Zealand.

Background: To examine risk factors for development of glaucoma in a large cohort of subjects with uveitis and scleritis.

Methods: Retrospective review of subjects diagnosed with uveitis or scleritis between 2006 and 2019 at Auckland District Health Board. Subjects were excluded if they had glaucoma due to another cause. Read More

View Article and Full-Text PDF

Phacoemulsification after trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease: intermediate-term visual outcome, IOP control and trabeculectomy survival.

BMC Ophthalmol 2022 May 9;22(1):210. Epub 2022 May 9.

Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.

Purpose: To evaluate the visual outcome, intraocular pressure control and trabeculectomy survival after phacoemulsification in eyes with prior trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease (VKH).

Design: Retrospective comparative study.

Methods: Eyes with uveitic glaucoma associated with VKH who underwent mitomycin C (MMC)-enhanced trabeculectomy were included. Read More

View Article and Full-Text PDF

Correspondence regarding: Review article: Ocular syphilis.

Surv Ophthalmol 2022 May 2. Epub 2022 May 2.

All India Institute of Medical Sciences, New Delhi, Delhi, India. Electronic address:

View Article and Full-Text PDF

Pattern of uveitis from a tertiary eye care center in Himalayan belt of North India.

Indian J Ophthalmol 2022 05;70(5):1642-1647

Department of Ophthalmology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India.

Purpose: To study the clinical characteristics of uveitis in patients presenting to a tertiary care institute in the northern part of India, predominantly serving the population of Himalayan belt.

Methods: In this retrospective descriptive case series, data of 141 eyes of 102 patients diagnosed between January 2019 and January 2021 were analyzed. Patients were diagnosed, named, and meshed as per the Standardization of Uveitis Nomenclature. Read More

View Article and Full-Text PDF

Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib.

Klin Monbl Augenheilkd 2022 04 26;239(4):572-574. Epub 2022 Apr 26.

Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland.

View Article and Full-Text PDF

Complications of uveitis in a Spanish population, UveCAM study.

Arch Soc Esp Oftalmol (Engl Ed) 2022 May 22;97(5):244-250. Epub 2022 Apr 22.

Servicio de Reumatología, Hospital Universitario Infanta Sofía, Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea, San Sebastián de los Reyes, Madrid, Spain.

Objective: To estimate the population frequency of uveitis complications and to evaluate their main risk factors in the patients with uveitis from the UVECAM study.

Patients And Methods: Development of complications in 386 patients with uveitis in the whole health area of the province of Toledo (UVECAM study) during a period of 1 year. Description of complications and study of their possible determinants by means of multivariate regression models. Read More

View Article and Full-Text PDF

The conundrum of clinical trials for the uveitides: appropriate outcome measures for one treatment used in several diseases.

Epidemiol Rev 2022 Apr 20. Epub 2022 Apr 20.

Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health.

The uveitides consist of over 30 diseases characterized by intraocular inflammation. Non-infectious intermediate, posterior, and panuveitides typically are treated with oral corticosteroids and immunosuppression with a similar treatment approach for most diseases. Because non-infectious intermediate, posterior and panuveitides collectively are considered a rare disease, single disease trials are difficult to impractical to recruit, and most trials have included several different diseases for a given protocol treatment(s). Read More

View Article and Full-Text PDF

Demographic and clinical features of pediatric uveitis and scleritis at a tertiary referral center in China.

BMC Ophthalmol 2022 Apr 18;22(1):174. Epub 2022 Apr 18.

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.

Background: To analyse demographic, clinical features, treatment and therapeutic outcomes of pediatric uveitis and scleritis patients.

Subjects: The clinical records of pediatric uveitis and scleritis cases between January 2012 and December 2020 at a tertiary uveitis service center in Tianjin Medical University Eye Hospital (TMUEH) were reviewed.

Results: In total, 209 patients (337 eyes) were included, 49. Read More

View Article and Full-Text PDF

Various clinical presentations of uveitis associated with durvalumab treatment.

Radiol Oncol 2022 04 12;56(2):129-137. Epub 2022 Apr 12.

University Eye Clinic, University Clinical Centre Ljubljana, Ljubljana Slovenia.

Background: Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-SCLC) and locally advanced unresectable (NSCLC). The present review aimed to analyse immune-mediated uveitis, secondary to durvalumab treatment, through a review of the literature and a presentation of two clinical cases. Read More

View Article and Full-Text PDF

Fitness to Serve in the Armed Forces and Internal Medicine: A Retrospective Study.

Mil Med 2022 Apr 12. Epub 2022 Apr 12.

Department of Internal Medicine, Bégin Military Teaching Hospital, Saint-Mandé 94160, France.

Introduction: Assessment of the medical fitness to serve in the armed forces has two objectives: to prevent the military operations from being jeopardized by a medical issue, and to protect soldiers from the sequelae of diseases that could become complicated in the operational field, especially in overseas operations where soldiers are exposed to a remote setting and a long evacuation time. Little is known about fitness decisions for soldiers with systemic or autoimmune diseases. Therefore, we conducted a single-center retrospective study of internal medicine fitness decisions. Read More

View Article and Full-Text PDF

Uveitis Patterns and Severity: An Epidemiologic Study from a Tertiary Care Private Referral Center in Buenos Aires, Argentina.

Ocul Immunol Inflamm 2022 Apr 11:1-7. Epub 2022 Apr 11.

School of Biomedical Sciences, Austral University, Buenos Aires, Argentina.

Purpose: To report uveitis' spectrum in a private practice cohort in the city of Buenos Aires, Argentina.

Methods: Retrospective review at Instituto de la Visión (November 2011-October 2015). Standard demographics, ethnicity and Native American aboriginal ancestry were recorded. Read More

View Article and Full-Text PDF

Intermediate uveitis: Etiologies and outcomes in a tertiary referral hospital in KSA.

Saudi J Ophthalmol 2021 Apr-Jun;35(2):81-83. Epub 2022 Feb 18.

Vitreoretinal Division , King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.

Purpose: The purpose of the study is to evaluate the common causes of intermediate uveitis (IU) and outcomes of this disease in patients presenting to King Khaled Eye Specialist Hospital (KKESH) in Riyadh, KSA.

Methods: This retrospective cohort study evaluated medical files of patients with IU was reviewed. A total of 109 patients were included in the study. Read More

View Article and Full-Text PDF
February 2022

Dynamic changes of Elschnig pearls posterior capsule opacification.

BMJ Case Rep 2022 Mar 29;15(3). Epub 2022 Mar 29.

Department of Ophthalmology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.

An adolescent female with underlying bilateral pseudophakia and idiopathic intermediate uveitis had reduced visual acuity due to posterior capsule opacification (PCO). The rapid progression and different morphological formations of Elschnig pearls were not influenced by the uveitis and immunosuppressive treatment. No capsulotomy was performed, and the PCO regressed spontaneously over time. Read More

View Article and Full-Text PDF

Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.

Medicina (Kaunas) 2022 Mar 21;58(3). Epub 2022 Mar 21.

Centre Hospitalier National des Quinze-Vingts, CIC 1423, DHU Sight Restore, 28 rue de Charenton, Sorbonne-Universités, Université Pierre et Marie Curie (UPMC), 75012 Paris, France.

: Secondary ocular localizations of hematological malignancies are blinding conditions with a poor prognosis, and often result in a delay in the diagnosis. : We describe a series of rare cases of ocular involvement in six patients with hematological malignancies, reportedly in remission, who presented secondary ocular localizations, challenging to diagnose. Two patients had an acute lymphoblastic leukemia (ALL) and developed either a posterior scleritis or a pseudo-panuveitis with ciliary process infiltration. Read More

View Article and Full-Text PDF

Targeted Medical History and Diagnostic Testing in Uveitis.

Klin Monbl Augenheilkd 2022 May 23;239(5):654-658. Epub 2022 Mar 23.

Immunbiologie, Universitäts-Augenklinik München, Deutschland.

Uveitis is a collective term for a variety of different intraocular inflammations. The underlying etiologies vary greatly depending on the uveitis subtype, and in particular the anatomical focus. The most common forms of anterior uveitis are acute fibrinous unilateral uveitis, often associated with the HLA-B27 haplotype, and granulomatous inflammation, typically associated with sarcoidosis or herpes infections. Read More

View Article and Full-Text PDF

Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.

Ophthalmol Ther 2022 Jun 19;11(3):1147-1161. Epub 2022 Mar 19.

Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.

Introduction: The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice.

Methods: This post-marketing surveillance was conducted at 60 medical facilities in Japan from October 2016 to June 2020. Patients with noninfectious intermediate, posterior, or panuveitis who were administered adalimumab (Humira, AbbVie Inc. Read More

View Article and Full-Text PDF

Uveitis intermedia as the initial presentation of a primary lymphoma of the central nervous system.

Arch Soc Esp Oftalmol (Engl Ed) 2022 Mar 17;97(3):168-171. Epub 2021 Nov 17.

Servicio de Neurología, Hospital Italiano de Buenos Aires, Argentina; Servicio de Oftalmología, Hospital Italiano de Buenos Aires, Argentina; Servicio de Hematología, Hospital Italiano de Buenos Aires, Argentina.

Primary central nervous system lymphoma is one of the most infrequent brain tumours, accounting for 3% of primary central nervous system neoplasms. In addition to its low prevalence, clinical presentation is usually nonspecific, leading to diagnostic delay. Intraocular involvement occurs in 15% of cases, and disease onset in this location is even rarer. Read More

View Article and Full-Text PDF

An analysis of the clinical profile of patients with uveitis following COVID-19 infection.

Indian J Ophthalmol 2022 03;70(3):1000-1006

Department of Uveitis, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Purpose: To describe the clinical profile of patients presenting with uveitis following COVID-19 infection at a tertiary care eye hospital in South India.

Methods: In this retrospective chart review, all consecutive cases presenting with an acute episode of intraocular inflammation and a history of COVID-19 infection diagnosed within the preceding 6 weeks, between March 2020 and September 2021, were included. Data retrieved and analyzed included age, sex, laterality of uveitis, and site of inflammation. Read More

View Article and Full-Text PDF

An Experience with Intravitreal Dexamethasone Implant for Uveitic Macular Oedema.

J Nepal Health Res Counc 2021 Dec 15;19(3):647-649. Epub 2021 Dec 15.

B. P. Koirala Lions Centre for Ophthalmic Studies, Department of Ophthalmology, Maharajgunj Medical Campus, Tribhuvan University, Institute of Medicine, Kathmandu, Nepal.

Intravitreal steroid implants are the latest trend for uveitis macular oedema treatment. Dexamethasone intravitreal implants are new in our contexts but we report 2 cases of uveitic cystoid macular oedema where this implant proved very useful in the treatment of recalcitrant macular oedema where other treatment modality fails. Two cases of non-infectious uveitis and intermediate uveitis with recalcitrant uveitic macular oedema underwent dexamethasone intravitreal implantation. Read More

View Article and Full-Text PDF
December 2021

Reply on Comments on the paper "Clinical characteristics and treatment of pars planitis: an adalimumab experience" by Ozdemir et al.

Graefes Arch Clin Exp Ophthalmol 2022 06 28;260(6):2067. Epub 2022 Jan 28.

Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, University of Health Sciences, Ankara, Turkey.

View Article and Full-Text PDF

Ultrasound biomicroscopy as a tool in the evaluation and management of ocular hypotony in uveitis.

Indian J Ophthalmol 2022 Feb;70(2):443-447

Department of Uveitis and Intraocular Inflammation, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Purpose: Chronic uveitis can lead to hypotony that may result in severe visual impairment. We highlight the use of ultrasound biomicroscopy (UBM) as an imaging tool to decide the modality of therapy and management of uveitic hypotony.

Methods: This was a retrospective hospital-based interventional case-series study that included a total of 36 eyes of 25 patients with uveitic hypotony seen between January 1997 and January 2020. Read More

View Article and Full-Text PDF
February 2022

Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.

Jpn J Ophthalmol 2022 Mar 19;66(2):130-141. Epub 2022 Jan 19.

Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan.

Purpose: Non-infectious uveitis associated with Vogt-Koyanagi-Harada (VKH) disease or sarcoidosis is commonly treated with systemic corticosteroids (SCS). We assessed the use of SCS for non-infectious uveitis relapses in Japanese clinical practice.

Study Design: Multicenter, retrospective chart review (UMIN Clinical Trial Registry; UMIN000032390). Read More

View Article and Full-Text PDF

Analysis of the clinical diagnosis and treatment of uveitis.

Ann Palliat Med 2021 Dec;10(12):12782-12788

Aier Eye Hospital, Tianjin, China.

Background: Uveitis is a not uncommon potentially sight-threatening intraocular inflammatory disorder and a major cause of blindness worldwide. Early diagnosis and effective treatment are very important to reduce complications and protect vision.

Methods: In a retrospective series, we enrolled 263 (390 eyes) consecutive uveitis patients, comprising 126 males and 137 females. Read More

View Article and Full-Text PDF
December 2021

Comments on the paper "Clinical characteristics and treatment of pars planitis: an adalimumab experience" by Ozdemir et al.

Graefes Arch Clin Exp Ophthalmol 2022 06 11;260(6):2065-2066. Epub 2022 Jan 11.

Department of Ophthalmology, University of Auckland, Auckland, New Zealand.

View Article and Full-Text PDF

Changes in Choroidal Vascularity Index (CVI) in Intermediate Uveitis.

Transl Vis Sci Technol 2021 12;10(14):33

National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Purpose: To investigate the longitudinal changes in choroidal vascularity index (CVI) in eyes with active and quiescent intermediate uveitis using enhanced depth imaging optical coherence tomography (EDI-OCT).

Methods: EDI-OCT images of eyes with active and quiescent intermediate uveitis were retrospectively reviewed and binarized using ImageJ software. Choroidal parameters including CVI, total choroidal area (TCA), luminal area (LA), stromal area (SA), and subfoveal choroidal thickness (SCT) were measured and compared between baseline and follow-up visits among eyes with active and quiescent intermediate uveitis. Read More

View Article and Full-Text PDF
December 2021